{"answer":{"query":"kisqali","resolved_as":"name","packages":11,"applications":["NDA209092"],"identity":{"application_numbers":["NDA209092"],"marketing_categories":["NDA"],"labelers":[{"text":"NOVARTIS PHARMACEUTICALS CORPORATION","untrusted":true}],"dosage_forms":[{"text":"TABLET, FILM COATED","untrusted":true}],"marketing_start":{"earliest":"2017-03-13","latest":"2017-03-13","packages_with_a_start_date":3}},"price":{"median_negotiated_over_nadac":null,"packages_compared":0,"packages_listed":11,"negotiated_price_ends":null,"rows":[{"ndc":"00078086001","name":{"text":"KISQALI FCT 200MG (x21) 200MG DAILY DOSE","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00078086714","name":{"text":"KISQALI FCT 200MG 14","untrusted":true},"class":"B","nadac_per_unit":346.94686,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00078086742","name":{"text":"KISQALI FCT 200MG(3X14) 400MG DAILY DOSE","untrusted":true},"class":"B","nadac_per_unit":346.94686,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00078087421","name":{"text":"KISQALI FCT 200MG 21","untrusted":true},"class":"B","nadac_per_unit":289.71673,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00078087463","name":{"text":"KISQALI FCT 200MG(3X21) 600mg DAILY DOSE","untrusted":true},"class":"B","nadac_per_unit":289.71673,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00078088821","name":{"text":"KISQALI FCT 200MG (x21)(200mg dosepack)","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00078089514","name":{"text":"KISQALI FCT 200MG(x14) (400mg dosepack)","untrusted":true},"class":"B","nadac_per_unit":346.94686,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00078090221","name":{"text":"KISQALI FCT 200MG (x21)(600mg dosepack)","untrusted":true},"class":"B","nadac_per_unit":289.71673,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00078090961","name":{"text":"KISQALI 200MG +FEMARA 2.5MG FCT 200MG DD","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00078091661","name":{"text":"KISQALI 200MG +FEMARA 2.5MG FCT 400MG DD","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00078092361","name":{"text":"KISQALI 200MG +FEMARA 2.5MG FCT 600MG DD","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null}],"negotiated_scheduled":null},"generic_entry":[{"application":"NDA209092","date":"2036-10-14","reading":"upper bound from listed dates, not a forecast","basis":"latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled)","driver":{"kind":"patent","ref":"10799506*PED","productNo":"001"},"latest_patent_expiry":"2036-10-14","latest_exclusivity_expiry":"2030-01-01","dated_barriers":28,"undated_barriers":0,"orange_book_edition":"2026-09","patents_listed":12,"exclusivities_listed":4,"fact_id":"bf9fa5f72c186f34aec92f5e"}],"label_history":{"events_total":15,"non_cmc_events":13,"counts_by_class":{"EFFICACY":7,"LABELING":6},"cmc_events":2,"recent_non_cmc_events":[{"application":"NDA209092","submission_no":27,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2026-07-01","documents":[{"type":"Letter","date":"2026-07-06","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/209092Orig1s027ltr.pdf","untrusted":true}},{"type":"Label","date":"2026-07-10","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/209092s027lbl.pdf","untrusted":true}}],"fact_id":"dcd1b470004250c5270e603e"},{"application":"NDA209092","submission_no":24,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2025-07-28","documents":[{"type":"Label","date":"2025-07-29","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209092s024lbl.pdf","untrusted":true}},{"type":"Letter","date":"2025-07-29","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/209092Orig1s024,209935Orig1s030ltr.pdf","untrusted":true}}],"fact_id":"9007e4ba528fea0e2c05de35"},{"application":"NDA209092","submission_no":23,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2025-02-11","documents":[{"type":"Letter","date":"2025-02-12","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/209092Orig1s023,209935Orig1s029ltr.pdf","untrusted":true}},{"type":"Label","date":"2025-02-19","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209092Orig1s023,209935Orig1s029lbl.pdf","untrusted":true}}],"fact_id":"51805897eeb1d9a109372736"},{"application":"NDA209092","submission_no":18,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2024-09-17","documents":[{"type":"Letter","date":"2024-09-19","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/209092Orig1s018, 209935Orig1s027ltr.pdf","untrusted":true}},{"type":"Label","date":"2024-10-25","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf","untrusted":true}}],"fact_id":"10f13936b49047cc079a33e9"},{"application":"NDA209092","submission_no":19,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2024-07-22","documents":[{"type":"Letter","date":"2024-07-23","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/209092Orig1s019ltr.pdf","untrusted":true}},{"type":"Label","date":"2024-07-24","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092s019lbl.pdf","untrusted":true}}],"fact_id":"67625d4cf28010dc74943f7a"}],"note":"a dated list of FDA supplements and their classes, not a reading of what changed in the label"},"substitution":{"products_total":1,"te_code_counts":{"NOT_PROVIDED":1},"marketing_status_counts":{"Prescription":1},"meaning":"raw FDA codes; the therapeutic equivalence code says whether FDA rates a generic as substitutable, and what that means for a given prescription is for a pharmacist or prescriber","products":[{"application":"NDA209092","product_no":"001","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"KISQALI","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"EQ 200MG BASE","untrusted":true}}]},"recalls":{"recalls_total":1,"counts_by_class":{"Class II":1},"packages_of_these_applications":3,"most_recent":[{"recall_number":"D-0799-2018","classification":"Class II","status":"Terminated","report_date":"2018-05-16","recall_initiated":"2018-04-03","recalling_firm":{"text":"Kroger Specialty Pharmacy, Inc.","untrusted":true},"reason":{"text":"Lack of Processing Controls.","untrusted":true},"packages_named":1,"fact_id":"baefdf59c6cc4d557e5c5041"}],"meaning":"FDA classifies the health hazard of a recall, not its effect on supply"},"supply":{"fda_shortage_status_counts":{},"packages_with_a_termination_date":6,"next_package_termination_dates":[],"packages_with_future_termination_date":0,"termination_meaning":"manufacturer-reported last-lot expiry or withdrawal date of one package; other packages and generics can remain"},"trials":{"attribution":"Source: ClinicalTrials.gov","modification_statement":"OmniRx has summarized and trimmed this ClinicalTrials.gov data.","not_an_offer":"A recruiting trial listing is not an offer of free drug and not medical advice; enrollment is decided by the study team.","ingredients":[{"ingredient":{"text":"RIBOCICLIB","untrusted":true},"recruiting_interventional_count":50,"not_yet_recruiting_count":15,"by_phase":{"PHASE3":13,"PHASE1/PHASE2":9,"NA":7,"PHASE2":16,"PHASE4":1,"PHASE1":3,"EARLY_PHASE1":1},"registry_processing_date":"2026-11-06T10:00:05","modifications":"Counts and phase tallies computed here from the full recruiting result set; trials trimmed to the 25 most recently updated, conditions to 3, countries to 10 distinct; no text edited.","recent_trials":[{"nct_id":"NCT03424005","title":{"text":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","untrusted":true},"phase":["PHASE1","PHASE2"],"sponsor":{"text":"Hoffmann-La Roche","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-06","start_date":"2018-03-30","link":{"text":"https://clinicaltrials.gov/study/NCT03424005","untrusted":true}},{"nct_id":"NCT07391774","title":{"text":"Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial","untrusted":true},"phase":["PHASE3"],"sponsor":{"text":"National Cancer Institute (NCI)","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-06","start_date":"2026-08-10","link":{"text":"https://clinicaltrials.gov/study/NCT07391774","untrusted":true}},{"nct_id":"NCT07214532","title":{"text":"Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer","untrusted":true},"phase":["NA"],"sponsor":{"text":"Natera, Inc.","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-05","start_date":"2026-05-08","link":{"text":"https://clinicaltrials.gov/study/NCT07214532","untrusted":true}},{"nct_id":"NCT07174336","title":{"text":"A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)","untrusted":true},"phase":["PHASE3"],"sponsor":{"text":"Eli Lilly and Company","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-04","start_date":"2025-12-22","link":{"text":"https://clinicaltrials.gov/study/NCT07174336","untrusted":true}},{"nct_id":"NCT04802759","title":{"text":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","untrusted":true},"phase":["PHASE1","PHASE2"],"sponsor":{"text":"Hoffmann-La Roche","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-03","start_date":"2021-06-22","link":{"text":"https://clinicaltrials.gov/study/NCT04802759","untrusted":true}}],"fact_id":"f088811dcc2460d4e1fd5247"}]},"assistance_and_offers":{"programs_listing_this_drug":[{"name":{"text":"Novartis Patient Assistance Foundation","untrusted":true},"type":"manufacturer","url":"https://pap.novartis.com/","status":{"state":"limited","effective":"2026-07-27","applies_to":{"text":"Novartis Patient Assistance Foundation applicants who applied on or after July 27, 2026","untrusted":true},"detail":{"text":"The Novartis Patient Assistance Foundation page states that for patients who applied for NPAF support on or after July 27, 2026, a new Patient Enrollment Portal is used: approved patients are encouraged to use it to re-fill medication, and patients told their application is missing information are encouraged to upload documents through it. The page lists no end date.","untrusted":true},"read_on":"2026-11-07T07:23:55.567Z","source_url":"https://pap.novartis.com/","proof_state":"verified"},"needs_status_check":true,"has_offer":false}],"manufacturer_offers":[],"note":"A program that lists a drug has not decided anything about any person: each program decides who qualifies, and a status other than open means it may not take new patients. Offers change and expire; read each offer's source and stated end date. A price figure is what the page states, not a quote."},"spending":{"reported_under":{"generic":{"text":"Ribociclib Succinate","untrusted":true},"brand":{"text":"Kisqali","untrusted":true}},"latest_year":2024,"series":[{"year":2020,"gross_spending_usd":128739775.94,"claims":10654,"beneficiaries":1623,"average_spending_per_claim_usd":12083.703392,"fact_id":"2967107ef3cac45064190a5c"},{"year":2021,"gross_spending_usd":119293639.85,"claims":9277,"beneficiaries":1435,"average_spending_per_claim_usd":12859.075116,"fact_id":"74e570e57b5b9a8937e11a56"},{"year":2022,"gross_spending_usd":166342357.81,"claims":11958,"beneficiaries":2108,"average_spending_per_claim_usd":13910.550076,"fact_id":"89aee0e07d6d10c56ddf8a10"},{"year":2023,"gross_spending_usd":370771679.06,"claims":24594,"beneficiaries":4543,"average_spending_per_claim_usd":15075.696473,"fact_id":"98d4903ffbcfdf2712013718"},{"year":2024,"gross_spending_usd":775493707.49,"claims":52578,"beneficiaries":8782,"average_spending_per_claim_usd":14749.395327,"fact_id":"c042928707596bd145730561"}],"rebate_caveat":"CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions.","not_a_patient_price":"Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.","meaning":"a drug-level aggregate of Medicare Part D claims for all manufacturers combined; not a formulary, not coverage","source":{"dataset":{"text":"data-year-2024, modified 2026-06-25","untrusted":true},"link":{"text":"https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-d-spending-by-drug","untrusted":true}}},"orphan_designation":{"ingredients":[{"ingredient":{"text":"ribociclib","untrusted":true},"designation_count":1,"approved_count":0,"recent":[{"designated":"2022-11-25","use":{"text":"Treatment of neuroblastoma","untrusted":true},"status":"Designated","sponsor":{"text":"Novartis Pharmaceuticals Corporation","untrusted":true},"approved":false}],"read_on":"2026-11-07T12:00:00.000Z","fact_id":"b49bedcfd5a83f0d1da24427"}],"reading":"a designation is not an approval and not a statement that the drug treats the condition; status is the FDA database's own"},"medicaid_state_utilization":{"year":2025,"states_with_data":23,"all_states_medicaid_reimbursed_usd":40718450.41,"all_states_medicaid_paid_prescriptions":2894,"top_states":[{"state":"AZ","medicaid_paid_prescriptions":267,"medicaid_reimbursed_usd":3993701.59,"total_reimbursed_usd":3993701.59,"packages":1,"covers":"fee_for_service_only","fact_id":"dbb3acb1e8b4656f151ed800"},{"state":"LA","medicaid_paid_prescriptions":268,"medicaid_reimbursed_usd":3810724.27,"total_reimbursed_usd":3958727.79,"packages":1,"covers":"all_record_types","fact_id":"f8a3fcf03b7f1392d4d7cbf8"},{"state":"MD","medicaid_paid_prescriptions":222,"medicaid_reimbursed_usd":3262837.73,"total_reimbursed_usd":3263354.73,"packages":1,"covers":"all_record_types","fact_id":"54b967d0696a529c351a6469"},{"state":"IA","medicaid_paid_prescriptions":191,"medicaid_reimbursed_usd":3149035.74,"total_reimbursed_usd":3149035.74,"packages":2,"covers":"fee_for_service_only","fact_id":"472a928f9074bf7d09e8e757"},{"state":"PR","medicaid_paid_prescriptions":166,"medicaid_reimbursed_usd":2440363.02,"total_reimbursed_usd":2518105.5,"packages":1,"covers":"all_record_types","fact_id":"f24ffb201d826b8aff68ffca"},{"state":"MA","medicaid_paid_prescriptions":164,"medicaid_reimbursed_usd":2437036.63,"total_reimbursed_usd":2437036.63,"packages":1,"covers":"fee_for_service_only","fact_id":"24ba5d98feb5dd2add2dd7c5"},{"state":"WV","medicaid_paid_prescriptions":144,"medicaid_reimbursed_usd":2145272.9,"total_reimbursed_usd":2182144.82,"packages":1,"covers":"all_record_types","fact_id":"85788d4fb46d7120f6ed1557"},{"state":"OK","medicaid_paid_prescriptions":95,"medicaid_reimbursed_usd":1742973.3,"total_reimbursed_usd":1742973.3,"packages":1,"covers":"fee_for_service_only","fact_id":"e00dd004ff298509af85d557"},{"state":"TN","medicaid_paid_prescriptions":118,"medicaid_reimbursed_usd":1732242.73,"total_reimbursed_usd":1732587.73,"packages":1,"covers":"all_record_types","fact_id":"ec7e6ae8e9315be6e982d1d2"},{"state":"AL","medicaid_paid_prescriptions":116,"medicaid_reimbursed_usd":1630558.16,"total_reimbursed_usd":1645260.52,"packages":1,"covers":"all_record_types","fact_id":"20823097b6f1391206c969d5"}],"unlabelled_state_code_xx":null,"built_from_facts":24,"facts_fee_for_service_only":9,"older_year_facts_not_used":51,"dataset":"State Drug Utilization Data 2025","read_on":"2026-11-07T22:41:44.201Z","reading":"Medicaid prescriptions and reimbursement by state (CMS State Drug Utilization Data). Reimbursement is before manufacturer rebates: not a net cost, not a patient price. Suppressed managed-care cells make a state figure fee-for-service only. An absent state was suppressed or unreported, not zero.","receipts_note":"a receipt is held for the largest fact behind each state shown; every figure is a sum of the built_from_facts facts, each recomputable from its recorded input hash"}},"receipts":[{"fact_id":"e3f36df704325e10ae7c7134","field":"ndc.listing","entity":"ndc:00078086001"},{"fact_id":"0666287aa2bb39ff1086e2af","field":"ndc.listing","entity":"ndc:00078086742"},{"fact_id":"dac77f4fba758fee974e8852","field":"ndc.listing","entity":"ndc:00078087463"},{"fact_id":"bf9fa5f72c186f34aec92f5e","field":"drug.generic_entry_earliest","entity":"application:NDA209092"},{"fact_id":"88e61e77cfefd790c831df5f","field":"drug.patent","entity":"application:NDA209092"},{"fact_id":"3c40a68fe4d013dd1a636d62","field":"drug.exclusivity","entity":"application:NDA209092"},{"fact_id":"dcd1b470004250c5270e603e","field":"drug.label_event","entity":"application:NDA209092"},{"fact_id":"9007e4ba528fea0e2c05de35","field":"drug.label_event","entity":"application:NDA209092"},{"fact_id":"51805897eeb1d9a109372736","field":"drug.label_event","entity":"application:NDA209092"},{"fact_id":"10f13936b49047cc079a33e9","field":"drug.label_event","entity":"application:NDA209092"},{"fact_id":"67625d4cf28010dc74943f7a","field":"drug.label_event","entity":"application:NDA209092"},{"fact_id":"aa38efc8abba2cbb805b6efb","field":"drug.marketing_status","entity":"application:NDA209092"},{"fact_id":"baefdf59c6cc4d557e5c5041","field":"ndc.recall","entity":"ndc:00078087463"},{"fact_id":"f088811dcc2460d4e1fd5247","field":"drug.trial_access","entity":"drug:ribociclib"},{"fact_id":"04e762d41a1aeb9b84c84d80","field":"program.status","entity":"program:cosentyx-patient-assistance"},{"fact_id":"2967107ef3cac45064190a5c","field":"drug.partd_spending","entity":"drug:ribociclib-succinate|kisqali"},{"fact_id":"74e570e57b5b9a8937e11a56","field":"drug.partd_spending","entity":"drug:ribociclib-succinate|kisqali"},{"fact_id":"89aee0e07d6d10c56ddf8a10","field":"drug.partd_spending","entity":"drug:ribociclib-succinate|kisqali"},{"fact_id":"98d4903ffbcfdf2712013718","field":"drug.partd_spending","entity":"drug:ribociclib-succinate|kisqali"},{"fact_id":"c042928707596bd145730561","field":"drug.partd_spending","entity":"drug:ribociclib-succinate|kisqali"},{"fact_id":"b49bedcfd5a83f0d1da24427","field":"drug.orphan_designation","entity":"drug:ribociclib"},{"fact_id":"dbb3acb1e8b4656f151ed800","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00078086742:AZ"},{"fact_id":"f8a3fcf03b7f1392d4d7cbf8","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00078086742:LA"},{"fact_id":"54b967d0696a529c351a6469","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00078086742:MD"},{"fact_id":"472a928f9074bf7d09e8e757","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00078086742:IA"},{"fact_id":"f24ffb201d826b8aff68ffca","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00078086742:PR"},{"fact_id":"24ba5d98feb5dd2add2dd7c5","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00078086742:MA"},{"fact_id":"85788d4fb46d7120f6ed1557","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00078086742:WV"},{"fact_id":"e00dd004ff298509af85d557","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00078087463:OK"},{"fact_id":"ec7e6ae8e9315be6e982d1d2","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00078086742:TN"},{"fact_id":"20823097b6f1391206c969d5","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00078086742:AL"}],"as_of":{"newest_fact_retrieved_at":"2026-11-10T20:02:39.475Z"},"edition":{"id":"2026-11","merkleRoot":"006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6","factCount":212100,"manifestPresent":true},"licence":{"classes":["AMBER","GREEN"],"note":"Source records are public; this compilation is cited with attribution. See the provenance tool for each fact's licence label."},"unknown":[{"code":"NO_DATA","field":"price.ratio","reason":"no package has both a brand-class NADAC price and a negotiated price in force"},{"code":"NO_DATA","field":"policy","reason":"no Federal Register event in the edition names this drug or its programs"},{"code":"NO_DATA","field":"biologic_status","reason":"no biologic application of this drug has a Purple Book status in the edition (a drug that is not a biologic has none)"},{"code":"NO_DATA","field":"payment_limit","reason":"no HCPCS code whose NDC crosswalk names a package of these applications has a Part B payment limit in the edition"},{"code":"NO_DATA","field":"rems","reason":"no REMS@FDA program is tied to these applications in the edition (most drugs have none)"},{"code":"NO_DATA","field":"controlled_schedule","reason":"no DEA schedule entry matched this drug's ingredient in the edition"},{"code":"NO_DATA","field":"safety_communication","reason":"no FDA Drug Safety Communication names this drug's ingredient in the edition"}],"disclaimer":"OmniRx is a reference layer of dated public facts, not clinical advice and not a guarantee of price, coverage or eligibility. Each answer lists the facts it rests on."}